Novacyt Sas · EURONEXT:ALNOV
Novacyt Sas — Novacyt — Investor Presentation (August 2021)
26 slides from Novacyt Sas's investor presentation, Aug 18, 2021
Slide 1: Investors Meeting
Investors Meeting 18 August 2021
Slide 2: Disclaimer
Disclaimer The document attached hereto and the presentation of which it forms part (together the “Materials”) have been prepared by Novacyt S.A. (“Novacyt” or the “Company”). The Materials are confidential and personal to you and are furnished to you as background information to provide a basis for
Slide 3: Agenda
Agenda • Strategy Overview – Graham Mullis • Test Menu Expansion – Trevor Reginald • Instrument Expansion – Paul Eros • Geographic Expansion – Guillermo Raimondo • Investment Case – James McCarthy • Summary & Wrap-up – Graham Mullis • Q&A Novacyt Group
Slide 4: Large, Fast Growing Market
Large, Fast Growing Market Global IVD Market 120 US$ 113.86B 100 80 US$ 69.52B 60 40 20 0 2020 2030 of which Molecular Diagnostics 2019 2030 US$8.3B US$21.0B
Slide 5: TO BE UPDATED – WHAT WE’VE ACHIEVED
TO BE UPDATED – WHAT WE’VE ACHIEVED Build on the success in COVID-19 testing to expand test menus in areas adjacent to COVID-19, and into additional prioritised market segments, delivery systems and geographies Test Menu Expansion Instrument Expansion Geographic Expansion Underpinned by compelling I
Slide 6: Strategy Update
Strategy Update Build on the success in COVID-19 testing to expand test menus in areas adjacent to COVID-19, and into additional prioritised market segments, delivery systems and geographies Test Menu Expansion Instrument Expansion Geographic Expansion Underpinned by compelling IVD market dynamics •
Slide 7: Innovation Centric, Patient Focused
Innovation Centric, Patient Focused • Innovation at the centre of Novacyt’s culture and operations • Focus on developing novel diagnostics for high unmet medical needs • Faster and more efficient diagnosis to create real patient benefit • Expanding test menu: ~26 new tests by end 2022
Slide 8: Best-in-Class Product Development
Best-in-Class Product Development First CE-marked COVID-19 test in 2020 First to UK market with variant testing in February 2021 First to UK market with Delta / Indian variant test in April 2021 First to UK market with Escape variants test in June 2021 Best-in-class direct to PCR assay
Slide 9: Best-in-Class Product Development
Best-in-Class Product Development Regulatory and Bioinformatics Clinical trials manufacturing scale-up
Slide 10: Industry leading in-house Bioinformatics capabilities
Industry leading in-house Bioinformatics capabilities • Industry-leading Bio-informatics platform • Applied to COVID, COVID-plus and post-COVID portfolio • Automated platform analyzes >2m genetic sequences per week • Machine learning approach identifies best diagnostic targets and best assay design
Slide 11: Industry-leading in-house clinical trial capabilities
Industry-leading in-house clinical trial capabilities • Industry-leading in-house clinical trial capabilities • Trials required to generate high quality patient data for regulatory filings and market access • Since Q4 2020, 15 trials in >20 UK & International locations • Showcases best-in-class clin
Slide 12: Regulatory and Manufacturing Scale-up
Regulatory and Manufacturing Scale-up • 16 new CE-IVD products registered since 2020 • 10 new products planned by end 2022 • In-house capability to file UK, EU, US, and international registrations • Integrated regulatory + clinical trials capacity allows rapid market access • Track record of scaling
Slide 13: Novacyt Focus
Novacyt Focus • Reagents • Instruments • Dedicated test kits
Slide 14: Molecular Diagnostics
Molecular Diagnostics Processing the sample Sample Nucleic acid Data collection and isolation and acquisition and PCR set up Run PCR stabilisation stabilisation result interpretation Novacyt Expertise and Focus in Molecular Diagnostics
Slide 15: PROmate® optimised workflow for genesig® q16 and q32
PROmate® optimised workflow for genesig® q16 and q32
Slide 16: Creating Optimised Workflow
Creating Optimised Workflow Automated sample handling Best-in-Class PCR Automated data acquisition & & PCR set up result reporting
Slide 17: Decentralised – Near Patient Testing
Decentralised – Near Patient Testing Decentralised Centralised Point of Care Near Patient High Throughput
Slide 18: Decentralised “Point-of-Impact” Testing
Decentralised “Point-of-Impact” Testing Q- Series Instrumentation • Small footprint • Optionality • Low complexity yet powerful • Small batches - improved throughput • Modular • Unique software genesig® q32 • Linking instruments genesig® q16 • Grow with workload
Slide 19: COVID-19 Portfolio
COVID-19 Portfolio Diagnostics solutions beyond disease progression Various diagnostics solutions that extend the life-cycle of revenue at different stage of disease progression
Slide 20: Novacyt´s Patient Focused Portfolio
Novacyt´s Patient Focused Portfolio Meeting different customer segments
Slide 21: Commercial footprint
Commercial footprint Maximising existing customer base and international presence Revenue split by region 1) Customer base >5000 customers Network >400 distributors Own commercial structure, doubled in 18 months Global presence Strong brand 2019 2020 H1 2021 1) Revenue excludes sales to DHSC UK & I
Slide 22: Top Line Growth
Top Line Growth Main pillars to bring us to the next level Share of Wallet Expansion Market Share Gains Maximising revenue streams of Generating new revenue streams our existing customer base • Leveraging menu expansion • Direct investments in UK, US, + • New instruments placements • Leveraging our
Slide 23: Investment Case
Investment Case Novacyt is committed to pioneering the next generation of diagnostics to meet a new era of global healthcare challenges with best, first to market, IP protected tests, driven by patient and clinician needs 2021 TARGETS Transition EBITDA Cash Revenues Gross Margins Conversion Margins
Slide 24: Summary – TO BE UPDATED
Summary – TO BE UPDATED • Rapid development of an extensive and innovative PCR COVID-19 product portfolio to address customer needs • Future of Novacyt secured • Repaid all long-term debt • Significantly strengthened the balance sheet • Delivered on a number of strategic objectives, including acquis
Slide 25: Q&A
Q&A Novacyt Group
Slide 26: Thank you for joining us at the 2021 Investors Webcast
Thank you for joining us at the 2021 Investors Webcast Thank you to all of our shareholders and employees for supporting the business through this transformative change Novacyt SA InvestorGraham contact details Mullis, Chief Executive Officer James McCarthy, Chief Financial Officer +44 (0)1276 60008